Galapagos (France)

Galapagos (France) is the French arm of Galapagos NV, a biotechnology company that began in 1999 with a handful of employees and a mission to pioneer medicines for patients. The French entity is associated with Romainville, France, and forms part of the group's European footprint alongside its Belgian headquarters in Mechelen and its U.S. sites in Chicago, Brisbane, San Francisco and South San Francisco. The parent group describes itself as a biotechnology company committed to improving the lives of people with severe diseases, and it has historically pursued drug discovery and development across immunology, inflammation and other serious disease areas. The French operation sits within a group that has undergone a significant strategic and identity shift. In April 2026, shareholders approved changing the company name from Galapagos NV to Lakefront Biotherapeutics NV, a move the company said reflected a new direction focused on transformational business development and a concentrated portfolio of breakthrough opportunities. The rebranding followed a period in which the group repositioned itself around a clinical-stage portfolio in immunology and inflammation, anchored by the lead asset gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases. As part of the wider organization, Galapagos (France) contributes to a company that combines disciplined business development with focused execution. The group has emphasized deal-making expertise, operational flexibility and a strong capital position, and it has pursued acquisitions and in-licensing to build its pipeline. Its leadership team, led by Executive Director and Chief Executive Officer Henry Gosebruch, includes executives responsible for finance, legal, strategy, medical affairs, business development and operations. For the French market specifically, the entity represents the group's local presence and point of contact, while the parent company's shares have been listed on Euronext and Nasdaq. The French subsidiary's role is therefore that of a national operating and research site within a larger international biopharmaceutical group, rather than an independent publicly traded company.

Galapagos (France) is the French entity of Galapagos NV, a biotechnology group whose story began in 1999 with a handful of employees and a dream to pioneer for patients. Over time, the group crystallized into a biotechnology company committed to improving the lives of people with severe diseases. The French operation, associated with Romainville, forms part of the group's European presence, complementing its headquarters in Mechelen, Belgium, and its U.S. locations in Chicago, Brisbane, San Francisco and South San Francisco. The parent group has undergone a major strategic and identity transformation. In April 2026, shareholders approved changing the company name from Galapagos NV to Lakefront Biotherapeutics NV. The company stated that the new name signals a forward-looking identity grounded in clarity, discipline, and ambition, and reflects a commitment to building a focused portfolio of breakthrough opportunities for patients while creating long-term value for stakeholders. This change followed a shift in direction toward transformational business development. A key element of the group's repositioning was the establishment of a clinical-stage portfolio in immunology and inflammation, anchored by the lead asset gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. In June 2026, together with Gilead Sciences, the company announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition added gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, which will be the foundation of the company's clinical development pipeline. Gamgertamig is designed to enable rapid and deep plasma cell and B cell depletion following a limited subcutaneously administered treatment course, with the potential to induce durable disease control in serious antibody-mediated orphan diseases including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). It has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027. The company also in-licensed a preclinical portfolio of three additional autoimmune-focused programs originally from Ouro, with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million per program. Within this evolving organization, Galapagos (France) serves as the group's French operating and research site. The parent company has emphasized disciplined business development, operational flexibility and a strong capital position, and its leadership team is led by Executive Director and Chief Executive Officer Henry Gosebruch. The French entity thus represents a national component of an international biopharmaceutical group that has been listed on Euronext and Nasdaq and continues to pursue high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value.

• 2026

  Shareholders approve changing the company name from Galapagos NV to Lakefront Biotherapeutics NV.

• 2026

  Together with Gilead Sciences, Lakefront announces the successful completion of the acquisition of Ouro Medicines.

• 1999

  Galapagos begins with a handful of employees and a dream to pioneer for patients.

A national operating and research site within an international biopharmaceutical group focused on immunology and inflammation.

• gamgertamig (OM336)

  A clinical-stage BCMAxCD3 T cell engager for autoimmune diseases, granted Fast Track and Orphan Drug Designation by the U.S. FDA for AIHA and ITP.

1. 1Locations - Lakefront Biotherapeuticslakefrontbio.com
2. 2Our story - Lakefront Biotherapeuticslakefrontbio.com
3. 3About Us - Lakefront Biotherapeuticslakefrontbio.com
4. 4Leadership - Lakefront Biotherapeuticslakefrontbio.com
5. 5Galapagos (France) - Wikidatawikidata.org